|
|
Article: DiscoveryBioMed Garners NIH Grant for Cystic Fibrosis Drug Research and Development.
- Article from:
- Health & Beauty Close-Up
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 Close-Up Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DiscoveryBioMed, Inc. (DBM) announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH).
In a release, the Company noted that the $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).
"SBIR funding is an essential part of DiscoveryBioMed's ability to provide our academic clients with cost-effective access to our world-class drug discovery engine," said Dr. Erik Schwiebert, Chief Executive Officer of DiscoveryBioMed. "By screening our test drugs on DBM's proprietary ...
Related newspaper, magazine, and journal articles:
|
|
Article: DiscoveryBioMed, Inc. Engaged in Multiple Projects on ...
Business Wire;
February 19, 2009 ;
700+ words
... ... amp; OCEANSIDE, Calif. -- DiscoveryBioMed, Inc. has agreed to move forward ... Cell Technology CEO Jeffrey Janus. "DiscoveryBioMed's proven expertise in assay development ... a variety of human tissues. ABOUT DISCOVERYBIOMED, INC. DiscoveryBioMed, Inc. is ...
|
|